| Press releases

Formycon Reports Financial and Operating Results for the First Half Year of 2017

Formycon has accomplished a successful first half year in 2017. Phase III clinical trial of FYB201 is continuing to progress as planned, the implementation of development cooperation agreement for FYB202 is anticipated for second half of the year

Calendar

German Equity Forum

November 27-29, 2017; Frankfurt/Germany

Financial reports
gb_teaser-16-illo

Annual Report 2016

Published on:
May 3, 2017

  • Teaser_mitglied-bio-deutschland-en
  • Forschungssiegel_Teaser_Webseite-en
  • Teaser_mitglied-biosimilar-medicines-en
  • teaser-powerlist
  • teaser-wachstumschampion-en
  • pipeline-en-teaser
  • slider04
  • slider06

Formycon is a leading independent pure play developer of biosimilars and has become a recognized innovator in this field. The company has extensive experience in the development of complex biological molecules. Formycon’s specialist expertise allows the company to develop high-quality biosimilars that meet the strict regulatory requirements of highly regulated markets such as Europe and the United States. Formycon currently has four biosimilars under development, with further product candidates already identified. Two biosimilar candidates have already been licensed out.